# Safety and Efficacy of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors After Acute Coronary Syndrome: A Meta-analysis of Randomized Controlled Trials

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/safety-and-efficacy-of-proprotein-convertase-subtilisin-kexin-type-9-inhibitors/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Ahmed Atia,Heba Aboeldahab,Ahmed Wageeh,M. Elneny,Mohamed Elmallahy,Bashaer Elawfi,Menna M. Aboelkhier,Amr Elrosasy,Maya Magdy Abdelwahab,Somaya Sayed,Ahmed Abdelaziz |
| Citations | 13 |
| DOI | 10.1007/s40256-023-00621-5 |
| Fields | Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://link.springer.com/content/pdf/10.1007/s40256-023-00621-5.pdf |
| OpenAlex ID | https://openalex.org/W4391032824 |
| PMID | 38241002 |
| Type | review |
| Year | 2024 |

## Paper authors

- [Amr Elrosasy](https://scholariq.org/researchers/amr-elrosasy/)

## Paper primary topic

- [Lipoproteins and Cardiovascular Health](https://scholariq.org/topics/lipoproteins-and-cardiovascular-health/)

## Paper topics

- [Lipoproteins and Cardiovascular Health](https://scholariq.org/topics/lipoproteins-and-cardiovascular-health/)
- [Coronary Interventions and Diagnostics](https://scholariq.org/topics/coronary-interventions-and-diagnostics/)
- [Antiplatelet Therapy and Cardiovascular Diseases](https://scholariq.org/topics/antiplatelet-therapy-and-cardiovascular-diseases/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.